GAC/Buffett - Since this is all considered hypothetical and highly speculative I will put my two cents in here as well.

A US listing, if it happens will be done prior to full trial results coming out I'm assuming since we will need money prior to then. So we get our US listing and raise 50 to 60 million to pay off Third Eye and have capital to operate and we sit there with between 90 and 200 million shares outstanding depending on whether we have done a consolidation of sorts. The Top Line results come out and they kick butt (if they don't everything else is mute). The share price then goes on a wild ride the likes of which we have never seen before. Speculation is now rampant about not only the diabetic cvd part of the trial but also CKD and cognitive function. In this scenario it is quite conceivable to see a market cap of 5 to 10 billion. We may or may not get an offer to be bought out at this time but there would certainly be a number of serious tire kicks around. A couple of months down the road the full trial results come out and the world now sees why the Top Line results kicked butt. Not only is there better than 30% RRR for the Top Line but there is extraordinary results for both CKD and cognitive function. In this situation it is very conceivable that there is the potential to have a mega blockbuster drug in not one but three separate indications. Hepalink would be one of the participants that may be bidding but there would be a number of very large players keeping a very close eye on the developments of this little biotech.

GAC you wondered why Rothchild's will be taking this to a US listing! If this even comes mildly close to my speculation, that's why.

Hepalink may be a bidder but they would have to pony up to the table with the largest in the industry... I hope.

Dreaming is fun sometimes.

Dyodd 

tada